Physician profile
Robert C Allison
NPI 1164753810
$6,208.83
in general payments reported to CMS, 2019-2025
23 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $955 · 2022: $1,322 · 2023: $1,375 · 2024: $1,960 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,847 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,847.31 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,553.40 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,044.01 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $928.30 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $782.88 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ironwood Pharmaceuticals, INC | $290.67 | 2022-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $273.76 | 2021-2025 | Rebyota |
| Aimmune Therapeutics, INC. | $212.94 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $202.75 | 2022-2024 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $148.49 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $132.45 | 2021-2023 | |
| Ardelyx, INC. | $115.43 | 2022-2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $84.86 | 2021-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $61.28 | 2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $49.83 | 2024 | Dupixent |
| Celgene Corporation | $49.82 | 2023-2024 | Zeposia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.80 | 2024 | |
| Amgen INC. | $44.11 | 2023 | Amjevita |
| Gilead Sciences, INC. | $40.41 | 2021-2024 | |
| Axonics, INC. | $37.64 | 2023 | Axonics |
| Blueprint Medicines Corporation | $36.31 | 2023 | |
| Daiichi Sankyo INC. | $28.76 | 2025 | Enhertu |
| Madrigal Pharmaceuticals | $20.64 | 2024 | Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.29 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.